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Abstract
Purpose: To compare the effectiveness of anal and perianal condylomata treatment using argon 
plasma and electrofulguration. 
Methods: From January 2013 to April 2014, 37 patients with anal and perianal condylomata, 
who had been diagnosed through proctological examination, oncotic cytology, polymerase chain 
reaction (PCR) and histology, underwent treatment with argon plasma and electrofulguration. 
The perianal and anal regions were divided into two semicircles. Each semicircle was treated 
using one of the methods by means of simple randomization. Therapeutic sessions were 
repeated until all clinical signs of infection by HPV were eliminated. The patients were evaluated 
according to several variables like the genotype of HPV, HIV infection, oncological potential per 
genotype, oncotic cytology and histology.
Results: Among all the variables studied, only immunosuppression due to HIV influenced the 
results, specifically when the fulguration method was used. There was no significant difference 
in effectiveness between argon and fulguration based on lesion relapse (p > 0.05). However, 
among HIV-positive patients, fulguration presented worse results, with a significant difference 
(p = 0.01).
Conclusion: Regarding treatment of anal and perianal condylomata acuminata, comparison 
between applying fulguration and argon demonstrated that these methods were equivalent, 
but use of fulguration presented more relapses among HIV-positive patients.
Key words: Condylomata Acuminata. Argon Plasma Coagulation. Electrosurgery. 
Papillomaviridae. HIV Seropositivity.
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the burn is deep and reaches the dermis or below 
this and the area treated is large, there is a risk of 
developing anal stenosis20-22. 
 Another factor that limits use of 
electrofulguration is the absence of any fine 
control regarding the depth of the burn and the 
infecting smoke produced. Care must be taken, 
particularly to avoid carbonization of tissue and 
formation of third-degree burns. These could 
develop as perineal infection, anal stenosis and 
even as gangrene4. Less than half of the patients 
treated have a complete response after a single 
session of electrofulguration16,20,22-26. Frequent 
follow-up is needed, to treat recurring lesions as 
soon as they are diagnosed20,23.
 Despite the various forms of treatment 
for condylomata, relapses are frequent and 
the results are unsatisfactory7,14-17,20,27. Use of 
argon plasma has arisen as an alternative to 
use of conventional electrofulguration given 
the promising results presented, although more 
studies are needed15,20,24,28. The present study had 
the aim of investigating this type of treatment for 
application among HIV-positive patients12,24-26,28.
 ■ Methods
 The present study consisted of a 
prospective investigation carried out among 
patients with anal condyloma or perianal 
condyloma, or both of these. The project for 
this study and the free and informed consent 
statement for use in this study were approved 
by the Research Ethics Committee, Universidade 
Federal de Minas Gerais (COEP-UFMG) 
89.531/2012, CAAE 06030112.5.0000.5149, 
and also by the Research Ethics Committee, 
Universidade Federal University de São Paulo 
(UNIFESP), under report number 1.156.495/2015 
and CAAE 46010115.3.0000.5505. This study was 
registered under universal trial number (UTN) 
U1111-1175-1767 and on the REBEC platform 
under number RBR-8YTCR4.
 Patients over the age of 18 years, 
 ■ Introduction
 Human papillomavirus (HPV) infection is 
the sexually transmitted disease most frequently 
diagnosed in both men and women. The incidence 
of this disease has been increasing over recent 
years almost everywhere in the world1-4. An 
estimated 10 to 20% of the adult sexually active 
population is infected by HPV, although only 1% 
presents classic condyloma and 2% present the 
subclinical disease, which could be diagnosed 
by means of high-resolution anoscopy4-8. Young 
adults are the group with the largest number of 
cases of infection, reaching rates of 46% among 
people aged between 20 and 30 years1-4,7,9. 
 Coinfection between the papillomavirus 
and human immunodeficiency virus (HPV-HIV) 
can reach more than 60% of individuals infected 
by HIV. This is a concerning situation, given the 
increasing number of cases of anal squamous cell 
carcinoma (SCC) among these diseased individuals. 
Tracking programs among this population have led 
to a concomitant increase in the number of cases 
diagnosed with condylomata acuminata1-4,9-10.
 Anal carcinoma used to be considered 
infrequent, but its frequency is growing, especially 
due to an increase in SCC11. At the same time, 
increased numbers of cases of anogenital infections 
due to the human papillomavirus, which causes 
condylomata acuminata, have been observed3,4,12. 
Early diagnosis, and correct treatment of the initial 
lesions are paramount for successful treatment 
of patients with condylomata acuminata as for 
anal carcinoma that may arise from such lesions. 
Diagnosing anal SCC at an early stage is often 
only possible due to the signs and symptoms 
caused by the condyloma. It is considered to be a 
warning sign and brings the opportunity to better 
investigate this at-risk population7,13-15.
 Conventional electrofulguration is 
considered to be one of the methods with lowest 
relapse rates among the surgical methods available 
for treating condylomata acuminata12,16-20. Proper 
application causes only a superficial burn, but if 
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with lesions caused by HPV over the whole 
circumference of the anal or perianal region, or 
both, were included in the present study. Patients 
who presented either unilateral condylomatous 
lesions or lesions that were too large for treatment 
at an outpatient service were not included. 
Patients who did not agree to participate in the 
study were also excluded. 
 From January 2013 to April 2014, a total 
of 93 patients were seen by the researchers 
at the coloproctology service for sexually 
transmitted diseases at the public center for 
specialized consultations of the municipality of 
Contagem, Minas Gerais. Out of this total, 46 
were eligible. However, only 37 participated 
in the entire study. The patients were studied 
prospectively for 24 weeks. 
 The patients underwent a clinical 
examination, blood count, coagulogram, fasting 
blood glucose, HIV test, cluster of differentiation 
count (CD4) (for the HIV-positive patients) and the 
Venereal Disease Research Laboratory test (VDRL) 
(Tables 1 and 2). Of these patients, 20 (54.1%) 
were smokers, 17 (45.9%) were non-smokers, 10 
(27%) had undergone some method of treatment 
previously and 27 (73%) had never been treated.
polymerase chain reaction (PCR) evaluations. 
 The results from the cytological 
analyses were distributed between: negative for 
intraepithelial lesion (NIL), low-grade squamous 
intraepithelial lesion (LSIL) and high-grade 
squamous intraepithelial lesion (HSIL). Specific 
genotypes were identified, risk groups were 
categorized and the number of genotypes per 
patient was identified. The histological analyses 
were categorized regarding the lesions caused by 
HPV and unspecific lesions. Patients with positive 
VDRL were also identified6,8 (Table 2).
Table 1 - Characterization of the laboratory 
variables (n = 37).
Variables n (%)
HIV
Positive 14 (37.8)
Negative 23 (62.2)
CD4
< 200 1 (7.14)
200 to 399 0 (0.0)
≥ 400 13 (92.86)
Total 14 (100.00)
Table 2 - Characterization of the variables 
from the complementary examinations (n = 
37).
Variables n (%)
VDRL
Positive 4 (10.8)
Negative 33 (89.2)
PCR
Positive 36 (97.3)
Negative 1 (2.7)
Genotype
HPV11 7 (14.0)
HPV16 5 (10.0)
HPV6 18 (36.0)
HPV18 2 (4.0)
HPV31 3 (6.0)
HPV33 3 (6.0)
HPV35 2 (4.0)
HPV56 2 (4.0)
HPV58 2 (4.0)
HPV68 1 (2.0)
HPV70 1 (2.0)
HPV72 1 (2.0)
Undefined type 2 (4.0)
Negative 1 (2.0)
Genotypes categorized as
High risk 21 (42.0)
Low risk 26 (52.0)
Others (negative or undefined type for the 
method used)
3 (6.0)
Impairment level per genotype
1 28 (82.4)
2 2 (5.9)
> 2 4 (11.8)
Total 34 (100.0)
Oncotic cytology
Negative for intraepithelial lesion 18 (48.6)
Low-grade squamous intraepithelial lesion 18 (48.6)
High-grade squamous intraepithelial lesion 1 (2.7)
Histological result
Condylomata acuminata 32 (86.5)
Unspecific lesions 5 (13.5)
 The condylomatous lesions were 
diagnosed by means of proctological 
examinations. These examinations consisted of 
static and dynamic inspection, rectal touching, 
anoscopy and high-resolution anoscopy using 3% 
acetic acid. All the patients underwent specimen 
collection for histology, oncotic cytology and 
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 Condylomata were treated by applying 
argon plasma and fulguration. To compare 
these two treatment methods, the anal 
and perianal region of the same individual 
was divided into two semicircles, following 
the model proposed by Billingham19. Each 
treatment method was applied to one 
semicircle, chosen by simple randomization. 
Applications were performed until the 
lesions disappeared, from a macroscopic 
point of view. The treatment was performed 
respecting the epithelial planes, with the 
objectives of improving results and minimizing 
complications, as described by Reid29. During 
the postoperative period, the patients were 
evaluated by means of fortnightly proctological 
examinations during the first month and then 
monthly examinations until the sixth month of 
follow-up. If residual lesions were diagnosed, 
new applications were performed, respecting 
the type of treatment previously performed on 
the given semicircle18,28.
 The results were analyzed statistically. 
Qualitative variables were described by means 
of the absolute frequency and percentages. 
Quantitative variables were assessed using the 
mean and standard deviation (SD). Pearson’s 
asymptotic and exact chi-square tests were 
used in the association analyses. The Z-test was 
initially used to analyze the effectiveness of the 
methods by comparing proportions. The Kappa 
test was then used to assess the agreement 
between the methods. The significance level 
was set at 0.05. The software used was the 
Statistical Package for the Social Sciences 
(SPSS), version 20.0, and Stata 9.1.
 ■ Results
 A total of 119 operations were 
performed among the 37 patients. Argon 
plasma was applied on the right side of 22 
patients and on the left side of 15. Fulguration 
was applied on the right side of 15 patients 
and on the left side of the other 22. Relapses 
were observed in 16 individuals (43.2%) who 
were treated with argon and in 19 individuals 
(51.4%) who were treated with fulguration, 
with no significant difference (p = 0.478). 
The variables of age group, gender, age when 
sexual life began, anal coitus, number of 
partners, smoking, anal manipulation, location 
of condylomata, previous treatment, cytology 
and HPV genotype were evaluated regarding 
their possible influence on relapses, but none 
of them showed statistically significant values.
 Statistical significance was only 
observed for the fulguration method when 
applied to seropositive patients, in comparison 
with seronegative patients (Table 3). The 
value of the Kappa agreement test regarding 
comparison of methods was 0.731 (p < 0.001).
 Since HIV was identified as a determining 
factor for a higher number of relapses in areas 
treated with fulguration, the patients were 
then categorized regarding the virus and CD4 
lymphocyte count. Statistical significance was 
observed for areas of seropositive patients 
even when the CD4 lymphocyte count was 
greater than 400 (Table 4).
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Table 3 - Results from analysis on the association between relapse after fulguration or argon 
treatment and the variables of the study.
Variable
Relapse
Fulguration Argon
Yes No p-Value Yes No p-value Total
Age group
≤ 30 years 9 (52.9) 8 (47.1) 0.8581 9 (52.9) 8 (47.1) 0.2721 17> 30 years 10 (50.0)  10 (50.0) 7 (35.0) 13 (65.0) 20
Gender
Female 2 (66.7) 1 (33.3) >0.9992 3 (100.0) 0 (0.0) 0.0722 3Male 17 (50.0) 17 (50.0) 13 (38.2) 21 (61.8) 34
Initiated sexual life at
≤ 20 years 18 (51.4) 17 (48.6) >0.9992 15 (42.9) 20 (57.1) 0.0722 35> 20 years 1 (50.0) 1 (50.0) 1 (50.0) 1 (50.0) 2
Number of partners
< 2 5 (31.3) 11 (68.8)
0.0772
5 (31.3) 11 (68.8)
0.2271
16
2 to 5 7 (77.8) 2 (22.2) 6 (66.7) 3 (33.3) 9
≥ 6 7 (58.3) 5 (41.7) 5 (41.7) 7 (58.3) 12
Anal coitus
Yes 16 (50.0) 16 (50.0) >0.9992 13 (40.6) 19 (59.4) 0.6342 32No 3 (60.0) 2 (40.0) 3 (60.0) 2 (40.0) 5
Anal manipulation
Yes 11 (50.0) 11 (50.0) 0.8422 9 (40.9) 13 (59.1) 0.7291 22No 8 (53.3) 7 (46.7) 7 (46.7) 8 (53.3) 15
Smoking
Yes 12 (60.0) 8 (40.0) 0.2541 10 (50.0) 10 (50.0) 0.3681 20No 7 (41.2) 10 (58.8) 6 (35.3) 11 (64.7) 17
HIV
Positive 11 (78.6) 3 (21.4) 0.0101 8 (57.1) 6 (42.9) 0.1831 14Negative 8 (34.8) 15 (65.2) 8 (34.8) 15 (65.2) 23
Location of the condylomata
Anal 3 (37.5) 5 (62.5)
0.8292
2 (25.0) 6 (75.0)
0.2322
8
Perianal 2 (66.7) 1 (33.3) 2 (66.7) 1 (33.3) 3
Perianal and anal 11 (52.4) 10 (47.6) 8 (38.1) 13 (61.9) 21
Other 3 (60.0) 2 (40.0) 4 (80.0) 1 (20.0) 5
Previous treatment
Yes 7 (70.0) 3 (30.0) 0.2692 6 (60.0) 4 (40.0) 0.2742 10No 12 (44.4) 15 (55.6) 10 (37.0) 17 (63.0) 27
Oncotic cytology
NIL 8 (44.4) 10 (55.6)
0.6252
7 (38.9) 11 (61.1)
0.6112
18
LSIL 10 (55.6) 8 (44.4) 8 (44.4) 10 (55.6) 18
HSIL 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0) 1
Genotype categorized as
High risk 7 (70.0) 3 (30.0)
0.1272
6 (60.0) 4 (40.0)
0.2232
10
Low risk 12 (50.0) 12 (50.0) 10 (41.7) 14 (58.3) 24
Others (negative or undefined 
type) 0 (0.0) 3 (100.0) 0 (0.0) 3 (100.0) 3
1Asymptotic Pearson’s chi-square test
2Exact Pearson’s chi-square test 
Table 4 - Results from analysis on the association between effectiveness variables and CD4.
HIV 
negative
HIV positive
Variables CD4 ≤ 400 CD4 > 400 Total p-Value
Argon relapse
       Yes 8 (34.8) 8 (34.8) 7 (58.3) 9 (75.0) 0.4732       No 15 (65.2) 15 (65.2) 5 (41.7) 3 (25.0)
Fulguration relapse
      Yes 1 (50.0) 2 (100.0) 16 19 0.0222      No 1 (50.0) 0 (0.0) 21 18
2Exact Pearson’s chi-square test.
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 ■ Discussion
 Operations using ionized argon gas 
(argon plasma), which is inert and non-toxic, 
are based on its physicochemical properties. 
This method allows transference of electrical 
energy generated by an electrosurgical unit to 
the target tissue24,28. The ionized gas transfers 
energy without contact between the electrode 
and the tissue surface, which enables energy 
distribution according to the impedance 
of the tissue. This distribution occurs in a 
predictable manner. As tissue composition 
changes, tissue conductivity also changes, 
thus avoiding points at which tissue lesions 
deepen with formation of eschar24,25,28. The 
ion flow generated and conducted by argon 
follows the path of least electrical resistance, 
regardless of the position of the electrode 
in relation to the tissue, and also regardless 
of the direction of the flow of the gas24,25,28. 
This phenomenon is advantageous when the 
treatment is performed in the anal canal, 
because it improves access to the squamous-
columnar transition28. 
 The depth of the burn caused by 
the method is predictable. It can reach only 
between 2 and 4 mm in thickness in either 
skin or mucosa, according to the flow and 
power used, which stops formation of deep 
lesions that would increase the chance of 
postoperative infection and pain24,25,28. The 
depth reached by argon plasma is more than 
sufficient to eradicate lesions caused by HPV, 
considering that by reaching depths of 2 mm, 
more than 90% of lesions are eradicated. In the 
perianal regions, the recommendation is to 
reach 1 mm in depth for skin with no hair and 
up to 2 mm in skin with hair20,24,25. Involvement 
of cutaneous appendices demands greater 
attention regarding the depth at which argon 
plasma is applied. Following this criterion, 
residual lesions are due more to the existence 
of compromised lateral margins than to 
insufficient depth of treatment28,29. 
 The sensitivity of the PCR method 
in this sample was almost 98%, while other 
studies in the literature found values close to 
75%5,30. 
 Genotypes 6 and 11 were the most 
common. A substantial number of patients 
with high-risk genotypes for anal carcinoma 
were also observed. Moreover, half of the 
patients presented lesions compatible 
with LSIL in their cytological evaluations. 
Regarding division of the genotypes into 
three categories, the high-risk and low-risk 
genotypes presented similar occurrence1,4,6,20. 
HPV genotyping, which today is more 
associated with scientific research than with 
clinical practice, can individualize patients 
who might be more susceptible to evolving 
to carcinoma, due to presence of a high-risk 
genotype such as types 16 or 181,2,4,27. 
 All the patients underwent biopsies. 
Lesions caused by HPV were confirmed in 32 
individuals (86.5%), while the histology of 
the remaining five was unspecific. Oncotic 
cytological evaluations were performed on 
all the patients, with sensitivity of 51.3% 
for detection of cytological lesions caused 
by HPV, which is in accordance with the 
literature7,8. Through combining evaluations 
using PCR, histology and cytology, diagnoses 
of HPV were made in the cases of 100% of the 
patients. This demonstrated that the methods 
complemented each other and can be included 
in systematization of treatments for patients 
with anal and perianal HPV infections, as 
proposed by Nadal et al.30 (Table 2). 
 The effectiveness of the methods for 
treating condylomata was measured through 
the number of sessions needed to eradicate 
the clinical lesions caused by HPV. The areas 
treated with fulguration underwent up to 
three therapeutic sessions, while areas treated 
with argon required up to four sessions. 
Although there was no statistical difference in 
the number of therapeutic sessions, the lower 
number of applications in the fulguration group 
may have been due to the aggressiveness of 
the method. Regarding the argon method, 
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more areas responded to a single therapeutic 
session (21 vs. 18), demonstrating, at least in 
theory, the greatest potential for eliminating 
subclinical reservoirs around the clinical 
lesion, although with no statistical difference. 
Eradication of condylomatous lesions among 
all the patients was reached after 120 days 
of treatment, which confirms data from the 
literature showing that different types of 
treatment need more than one session to 
eradicate clinical lesions20. 
 None of the variables studied, with 
the exception of HIV, was able to influence 
the response to treatment of either method. 
The epidemiology and pathogenesis of 
condylomata caused by different viral 
genotypes, particularly the most aggressive 
types, may indicate which patients should be 
referred for differentiated follow-up because 
they have greater chances of evolving to 
carcinoma of anal and perianal squamous 
cells2,11,12,20. Genotypes that were more 
aggressive from an oncogenic point of view 
were expected to lead to a greater number of 
relapses, but there was no difference between 
treatments1,13. The HPV genotype did not 
influence the number of relapses (Table 3). 
 The relapse rate was higher among 
HIV-positive patients when the condylomata 
was treated using electrofulguration. This 
was observed through the greater number 
of sessions needed, in comparison with 
seronegative even when the CD4 lymphocyte 
count was greater than 400 (Table 4). This was 
not seen with use of argon. In this case, the 
areas treated among HIV-negative and HIV-
positive patients did not present any statistical 
difference regarding the number of relapses 
(Table 3).
 ■ Conclusions
 The application of argon plasma 
or fulguration to treat anal and perianal 
condylomata showed similar effectiveness. 
However, application of argon plasma was not 
influenced by serological factors, compared with 
fulguration, which was statistically less effective 
in treating HIV-positive patients.
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On page 486 of the original publication, instead of this Table 4:
Erratum
Table 4 - Results from analysis on the association between effectiveness variables and CD4.
HIV 
negative
HIV positive
Variables CD4 ≤ 400 CD4 > 400 Total p-Value
Argon relapse
       Yes 8 (34.8) 8 (34.8) 7 (58.3) 9 (75.0) 0.4732       No 15 (65.2) 15 (65.2) 5 (41.7) 3 (25.0)
Fulguration relapse
      Yes 1 (50.0) 2 (100.0) 16 19 0.0222      No 1 (50.0) 0 (0.0) 21 18
2Exact Pearson’s chi-square test.
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